Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Account Payables

Amounts the company owes suppliers for goods and services received.

Compugen Ltd.NASDAQ: CGEN

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 76.9% from a year ago

Account payables stood at $2.53M at the end of Q1 FY2026, down 76.9% from a year earlier and up 7.4% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Account payables amounted to 1.7% of total assets at the end of Q1 FY2026, down 7.7 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -76.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.53M+7.4% QoQ
Last fiscal yearDec 2025
$2.35M+28.0% YoY
Year agoMar 2025
$10.94M-76.9% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.9%——
1 year+28.0%——
3-year CAGR+9.9%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
2.35M USD
Year-over-year change
+28.0%
4-year CAGR
-15.5%

Account Payables vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -76.9% is the 8th highest of 9, against a peer median of +54.0%.
  • Account payables amounts to 1.7% of total assets for CGEN, versus a peer median of 4.5%.
CGEN Competitors
Account Payables for CGEN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€15.04M EUR+89.8%+3.3%24.0%
MISTMilestone Pharmaceuticals Inc.Mar 2026$10.02M USD+320.4%+35.6%5.2%
TNXPTonix Pharmaceuticals Holding Corp.Mar 2026$9.65M USD+130.1%+0.2%3.7%
CRDFCardiff Oncology, Inc.Mar 2026$5.48M USD+51.0%+60.5%11.1%
NVCTNuvectis Pharma, Inc.Mar 2026$4.7M USD+56.9%+29.2%18.5%
CGENCompugen Ltd.Mar 2026$2.53M USD-76.9%+9.9%1.7%
MOLNMolecular Partners AGMar 2026CHF 1.92M CHF-19.9%-2.0%2.2%
RANIRani Therapeutics Holdings, Inc.Mar 2026$858K USD-43.6%-40.4%1.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$435K USD-89.3%+0.6%0.3%
Peer median (excluding CGEN) —+54.0%+1.9%4.5%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents7.8M11.06M13.89M18.23M90.6M
Short-term Investments109.25M72.29M36.8M85.03M55.04M
Net Receivables188K317K61.32M269K294K
Inventory00000
Other Current Assets713K362K365K00
Total Current Assets123.22M86.13M114.58M106M148.02M
Property, Plant & Equipment (Net)3.91M3.36M2.55M3.7M3.2M
Goodwill00000
Intangible Assets00000
Long-term Investments0000410K
Tax Assets0000303K
Other Non-current Assets5.04M4.69M4.21M5.3M4.94M
Total Non-current Assets8.94M8.05M6.76M9M8.85M
Total Assets132.16M94.18M121.33M115M156.87M
Account Payables4.62M1.77M3.5M1.84M2.35M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0011.15M9.63M10.97M
Other Current Liabilities6.93M3.14M3.13M3.07M3.05M
Total Current Liabilities17.1M11.92M26.27M20.16M22.57M
Long-term Debt00000
Deferred Tax Liabilities0000303K
Deferred Revenue (Non-current)0025.39M34.05M24.94M
Other Non-current Liabilities6.39M3.27M3.4M3.41M3.89M
Total Non-current Liabilities8.37M4.58M29.51M39.92M31.57M
Total Liabilities25.47M16.5M55.78M60.08M54.14M
Common Stock239K240K247K248K262K
Retained Earnings(422.08M)(455.77M)(474.53M)(488.76M)(453.42M)
Accumulated OCI002K11K8K
Other Stockholders Equity00000
Minority Interest00000
Total Equity106.69M77.68M65.56M54.91M102.73M
Total Debt2.75M1.93M1.35M2.91M2.96M
Net Debt(5.05M)(9.13M)(12.54M)(15.32M)(87.64M)

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.